CHRFAM7A

Across TCGA pan-cancer cohorts, CHRFAM7A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHRFAM7A data layer compared with 18 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CHRFAM7A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHRFAM7A expression acts as an unfavorable survival marker.

LUAD, READ, and COAD are the cancer types where CHRFAM7A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.171	0.835	<.001	24	view →
READ	DFS	Median	All	0.084	0.845	<.001	12	view →
COAD	DFS	Median	II,III,IV	0.264	0.662	.048	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHRFAM7A–LUAD (OS)

Open the LUAD breakdown →